Michael J. Georgetson

Dr. Michael J. Georgetson


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAbdullah Sultany
Abdullah Sultany
ARAdishwar Rao
Adishwar Rao
AGAmlish Gondal
Amlish Gondal
ATAbhinay Theli
Abhinay Theli
RCRahul Chikatimalla
Rahul Chikatimalla
MGMichael J. Georgetson
Michael J. Georgetson
Background/Objectives: Perforated peptic ulcer (PPU) represents a surgical emergency with substantial morbidity and mortality. Despite declining overall peptic ulcer disease (PUD) incidence, contemporary population-based data comparing outcomes between perforated and non-perforated PUD remain limited, particularly during the COVID-19 pandemic. This study aimed to characterize the clinical and economic burden of PPU and identify independent predictors of adverse outcomes. Methods: We conducted a retrospective cohort study using the National Inpatient Sample (2016–2021), identifying 2,561,379 weighted hospitalizations for PUD. Hospitalizations were stratified by the presence (n = 207,970, 8.1%) or absence (n = 2,353,409, 91.9%) of perforation. The primary outcome was in-hospital mortality; secondary outcomes included sepsis, septic shock, acute kidney injury (AKI), prolonged length of stay (≥7 days), and high healthcare costs (≥$12,000). We performed 1:1 propensity score matching and multivariable logistic regression to assess independent predictors of adverse outcomes in the PPU cohort. Results: After propensity matching, PPU demonstrated significantly higher mortality than non-perforated PUD (7.2% vs. 3.0%, p < 0.001), along with increased rates of sepsis (21.8% vs. 8.2%, p < 0.001), septic shock (12.9% vs. 3.5%, p < 0.001), and AKI (29.5% vs. 22.8%, p < 0.001). Nearly half (45.6%) of PPU admissions exceeded 7 days, and 69.2% incurred costs ≥$12,000. Among PPU hospitalizations, multivariable analysis identified age ≥ 65 years (aOR 5.79, 95% CI 4.60–7.28), liver cirrhosis (aOR 1.93, 95% CI 1.62–2.30), chronic heart failure (aOR 1.73, 95% CI 1.56–1.92), and concurrent COVID-19 infection (aOR 4.35, 95% CI 3.46–5.47) as independent predictors of mortality. Chronic kidney disease strongly predicted AKI (aOR 2.81, 95% CI 2.64–2.98). Mortality increased from 6.9% (2016) to 8.0% (2021) in PPU hospitalizations (p < 0.001 for trend), with higher rates observed during the 2020 to 2021 period that coincided with the COVID-19 pandemic. Conclusions: Perforation complicates approximately 8% of hospitalized PUD cases but accounts for disproportionate mortality, sepsis, organ failure, and healthcare costs. Older age, cirrhosis, heart failure, and chronic kidney disease identify high-risk PPU patients requiring intensive monitoring and aggressive management. These findings support risk-stratified approaches focused on timely diagnosis, source control, and sepsis management to reduce the clinical and economic burden of PPU.